GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALEC-04 overview
ALEC-04 is under development for the treatment of solid tumor, hepatocellular carcinoma, cholangiocarcinoma, and recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with tumor locations including oropharynx, oral cavity, hypopharynx, larynx, nasopharynx. It acts by targeting claudin 1 (CLDN1).
Alentis Therapeutics overview
Alentis Therapeutics is a clinical-stage biotech company. It develops first-in-class anti-Claudin-1 (CLDN1) antibodies for treating positive tumors and organ fibrosis. The company’s oncology and ADCs (Antibody-Drug Conjugates) pipeline products include ALE.C04 an investigational first-in-class monoclonal antibody designed to treat cancer by targeting exposed Claudin-1 on solid tumors and ALE.P02 and ALE.P03 ADC for the treatment of Claudin-1 Positive Tumors. Alentis Therapeutics’ other pipeline includes Lixudebart for treating ANCA-associated vasculitis, advanced liver fibrosis and idiopathic pulmonary fibrosis. It also investigates next-gen CLDN1 modalities. Alentis Therapeutics is headquartered in Allschwil, Switzerland.
For a complete picture of ALEC-04’s drug-specific PTSR and LoA scores, buy the report here.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
